AstraZeneca Clinical Trials

Clinical trials sponsored by AstraZeneca — phases, conditions and reported results. Data from ClinicalTrials.gov.

• A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
  Phase 2 · Urinary Bladder Neoplasms · Active, not recruiting · Oct 26, 2022
• Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel
  Phase 2 · Ovarian Cancer · Active, not recruiting · Dec 10, 2012
• A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unrese
  Phase 3 · Non Small Cell Lung Cancer · Active, not recruiting · Apr 3, 2025
• A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
  Phase 1/2 · Triple Negative Breast Neoplasms · Active, not recruiting · Feb 2, 2026
• Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Wit
  Phase 3 · Non-small Cell Lung Cancer · Active, not recruiting · Jul 23, 2025
• Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared
  Phase 3 · Fallopian Tube Clear Cell Adenocarcinoma · Active, not recruiting · Mar 12, 2021
• A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on
  Phase 3 · Uncontrolled Hypertension · Completed · Jul 30, 2026
• A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amp
  Phase 2 · Non-Small Cell Lung Cancer · Active, not recruiting · Sep 24, 2024
• Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chem
  Phase 3 · Platinum Sensitive · Active, not recruiting · Feb 7, 2018
• Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
  Phase 2 · Lung Cancer Stage II · Active, not recruiting · Aug 29, 2024
• Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinom
  Phase 3 · Hepatocellular Carcinoma · Active, not recruiting · Jun 18, 2023
• Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squa
  Phase 2 · Non-Small Cell Lung Cancer Metastatic · Terminated · May 19, 2026
• Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment
  Phase 3 · Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV · Active, not recruiting · Aug 29, 2017
• Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With
  Phase 3 · Muscle Invasive Bladder Cancer · Active, not recruiting · Jul 3, 2025
• Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small C
  Phase 3 · Small Cell Lung Carcinoma Extensive Disease · Active, not recruiting · Mar 4, 2021

Trials by company

PfizerMerck (MSD)RocheNovartisAstraZenecaJohnson & Johnson (Janssen)Bristol Myers SquibbSanofiGSKEli LillyAbbVieAmgenBayerBoehringer IngelheimNovo NordiskTakedaGilead SciencesModernaBioNTechRegeneronVertexBiogenDaiichi SankyoAstellas PharmaEisaiOtsukaServierIncyteCelltrionSamsung BioepisHanmi PharmaceuticalYuhan

All trials